

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Lagan Seamus		2. Issuer Name and Ticker or Trading Symbol Rennova Health, Inc. [RNVA]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CEO and President	
(Last) (First) (Middle) 400 S. AUSTRALIAN AVE., SUITE 800		3. Date of Earliest Transaction (Month/Day/Year) 07/17/2016			
(Street) WEST PALM BEACH,, FL 33401		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned			

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/17/2016		A		333,334	A	\$ 0.3	344,234	D	
Common Stock	07/25/2016		J(1)		333,334	A	\$ 0.3 (1)	755,261	I	By: Alcimed LLC
Common Stock	08/05/2016		J(2)		1,171,667	A	\$ 0.3 (2)	1,926,928	I	By: Alcimed LLC

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)



Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Options to Purchase Common Stock	\$ 0.3	07/17/2016		A		250,000		07/17/2016	07/17/2026	Common Stock	250,000	\$ 0	250,000	D	
Options to Purchase Common Stock	\$ 0.3	07/17/2016		A		250,000		12/31/2016	07/17/2026	Common Stock	250,000	\$ 0	250,000	D	
Options to Purchase Common Stock	\$ 0.3	07/17/2016		A		250,000		12/31/2017	07/17/2026	Common Stock	250,000	\$ 0	250,000	D	
Options to Purchase Common Stock	\$ 0.3	07/17/2016		A		250,000		12/31/2018	07/17/2026	Common Stock	250,000	\$ 0	250,000	D	
Options to Purchase Common Stock	\$ 0.3	07/17/2016		A		500,000		(3)	07/17/2026	Common Stock	500,000	\$ 0	500,000	D	
Options to Purchase Common	\$ 0.3	07/17/2016		A		500,000		(4)	07/17/2026	Common Stock	500,000	\$ 0	500,000	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lagan Seamus 400 S. AUSTRALIAN AVE., SUITE 800 WEST PALM BEACH,, FL 33401	X	X	CEO and President	
Alcimedede LLC 400 S. AUSTRALIAN AVE., SUITE 800 WEST PALM BEACH,, FL 33401				Affiliated

Signatures

/s/ Seamus Lagan		09/14/2016
		Date
Alcimedede LLC By: /s/ Seamus Lagan, Sole Manager		09/14/2016
		Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Alcimedede LLC received the shares in lieu of a \$100,000 cash payment for services rendered.
- (2) Alcimedede LLC received the shares in exchange for the cancellation of outstanding debt.
- (3) The options become first exercisable upon the Issuer attaining \$75 million in gross revenue in any of the Issuer's three fiscal years from the date of grant through December 31, 2018.
- (4) The options become first exercisable upon the Issuer attaining a \$100 million market capitalization at any time during the three year period ending July 17, 2019.

Remarks:

Exhibit List - Exhibit 99 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Form 4 - Joint Filer Information

Name: Alcimedede LLC

Address: 400 South Australian Avenue, 8th Floor
West Palm Beach, FL 33401

Designated Filer: Seamus Lagan

Issuer & Ticker Symbol: Rennova Health, Inc. (RNVA)

Date of Earliest Transaction
Required to be Reported
(Month/Day/Year): July 17, 2016

Relationship of Reporting Person
to Issuer: 10% Owner

Individual or Joint/Group Filing: Form filed by More than One Reporting Person

Signature: Alcimedede LLC

By: /s/ Seamus Lagan
Seamus Lagan, Sole Manager